At the moment, Latvia is not considering using the Russian Covid-19 Sputnik V vaccine because it is not registered in the EU. But if it is, Health Minister Daniel Pavļuts does not see any problems for its use in Latvia. He said this on the air of the LTV7 program “Points above i”. The minister pins most of his hopes on the AstraZeneca vaccine writes Lsm. lv.
When asked if Latvia was ready to use the Russian “Sputnik,” Daniel Pavļuts said that “at this stage – definitely not.
“This vaccine has not been tested in the laboratories of organizations that Latvia trusts and cooperates with – European Union countries and partners. And as far as I know, the parameters for development and clinical trials have not been provided sufficiently for the use of this vaccine in the EU. If it is registered in the EU, I don’t see a problem. We will use those vaccines that are approved by the EU. And most of all we are waiting for a vaccine from AstraZeneca,” the minister said.
According to Pavļutsa, the vaccine from AstraZeneca may be approved for use in the EU on January 29. According to him, it is not the cheapest vaccine when compared to competitors, but it “was developed by scientists from scientific structures, universities, and not so much by pharmaceutical companies.”
“It was conceived as a vaccine to save the planet, not a business project. And it is based on an already proven method. And it was designed to be cheap enough and easy enough to mass-produce. That’s the result,” Pavluts said.
He acknowledged that the vaccine is very different from Pfizer because the latter is much more expensive and difficult to store and distribute. The advantage of AstraZeneca, on the other hand, is the ease of storage and use, but its registration at the level of the European Medicines Agency has been delayed.
Earlier, Janis Zvejnieks, deputy head of the State Agency of Medicines, spoke about the possibility of registration of Sputnik V in the territory of the European Union. On the air of the program “Points above i” of the Russian LTV7 broadcast he noted that any vaccine producer, including the Russian one, has all opportunities to register the preparation in the territory of the European Union after fulfilling all the requirements set by the European Medicines Agency.
As reported earlier, Latvia and five other EU countries sent a joint letter to the European Commission, where they urged to accelerate vaccine supplies from American company Pfizer and its German partner BioNTech.